skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

The Respiratory Effectiveness Group (REG) Summit, which took place on 28–29 June 2014, provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. This white paper presents research from studies identified of particular relevant to the asthma and COPD markets which revealed:

 

  • The potential benefits that Symbicort (budesonide/formoterol; AstraZeneca) may have over Spiriva (tiotropium; Boehringer Ingelheim) in the treatment of COPD in terms of both patient outcomes, as assessed by measuring COPD exacerbations, and healthcare utilization costs.
  • The value of add-on Spiriva therapy in asthma as Boehringer Ingelheim prepares to expand Spiriva’s indications in the EU.
  • That inhaled corticosteroid (ICS)/long-acting beta 2 agonist (LABA) therapy can improve long-term outcomes among patients that have experienced a severe asthma exacerbation.
  • That the prescribing behavior of physicians does not necessarily fall in line with step-up therapy guidelines.

Research highlights from this whitepaper include:

The potential benefits that Symbicort (budesonide/formoterol; AstraZeneca) may have over Spiriva.

The Value of add-on Spiriva therapy in asthma as Boehringer Ingelheim prepares to expand Spiriva's indications in the EU.

 

.

REG-summit-white-paper
Download whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now